AllCells

02/19/2025

Successful development and clinical translation of CAR-NK therapies starts at the source— high-quality leukopaks collected from well-characterized donors are essential to mitigate risks and delays. Read our latest blog to learn more: https://lnkd.in/e5eY25QG

hashtag hashtag hashtag

11/15/2024

The recording of our LinkedIn Live “Overcoming the Challenges of Allogeneic PBMC Isolation in GMP Manufacturing Workflow” is now available. Watch the replay here: https://allcells.com/webinars/overcoming-the-challenges-of-allogeneic-pbmc-isolation-in-gmp-manufacturing-workflow/?utm_source=LinkedIn&utm_medium=Organic+Social&utm_campaign=Q4+24+-+CGT+-+GMP+PBMCs+Webinar

To learn more about GMP Cryopreserved PBMCs, visit our website: https://allcells.com/gmp/gmp-cryopreserved-pbmcs/?utm_source=LinkedIn&utm_medium=Organic+Social&utm_campaign=Q4+24+-+CGT+-+GMP+PBMCs+Webinar

11/13/2024

Join us today for an insightful LinkedIn Live session with Dr. Yuki Kato Maves who will present a real-world case study highlighting how we partnered with a CGT developer to optimize the isolation workflow of GMP cryopreserved peripheral blood mononuclear cells (PBMCs).

https://www.linkedin.com/events/overcomingthechallengesofalloge7260303368554717184/theater/

See you at 3pm ET / 12pm PT!

Manufacturing failures in cell and gene therapy (CGT) carry high costs and risks, jeopardizing the timely production and delivery of safe, effective, and scalable allogeneic therapies. In this LinkedIn Live event, Dr. Yuki Kato Maves will present a real-world case study highlighting how Discovery Li...

11/07/2024

How did Discovery’s initiative with a CGT developer significantly reduce the risk of failure and CDMO costs?

Tune into our upcoming LinkedIn Live event on 11/13, where Dr. Yuki Kato Maves will present a real-world case study highlighting how we partnered with a CGT developer to optimize the isolation workflow of GMP cryopreserved peripheral blood mononuclear cells (PBMCs), resulting cost and risk reductions.

Register now:

Manufacturing failures in cell and gene therapy (CGT) carry high costs and risks, jeopardizing the timely production and delivery of safe, effective, and scalable allogeneic therapies. In this LinkedIn Live event, Dr. Yuki Kato Maves will present a real-world case study highlighting how Discovery Li...

10/14/2024

Are you planning to attend the 6th TIL Therapies Summit at the Colonnade Hotel in Boston next week? Schedule a meeting with us to learn more about how AllCells RUO and GMP products can help advance the tumor-infiltrating lymphocyte therapy development.

Schedule a Meeting: https://dls.com/event/til-therapies-summit/

Connect with Conor Marino for more information.

09/10/2024

We're excited to partner with ScaleReady in the inaugural G-Rex® Grant Program—a $20M initiative aimed at advancing CGT development and manufacturing.

Discovery Life Sciences specializes in leukapheresis and custom prospective collections of high-quality CGT starting materials. Through this partnership, G-Rex® Grant recipients gain access to exclusive offers on AllCells® RUO and GMP products.

Learn more: https://www.scaleready.com/g-rex-grant-program/

Discovery’s AllCells RUO and GMP products, combined with integrated analytical services, have supported many CGT programs in transitioning from early discovery to process development and manufacturing, with an average 98% collection deliverability rate.

Connect with us today to discuss your CGT projects: https://allcells.com/contact-us/

llustrates how ScaleReady works in a true partnership with your T and NK cell therapy program...

09/09/2024

Join our CGT team at Booth 38 during the 9th Annual CAR-TCR Summit. Our team is excited to be back in Boston from September 17-19 at the Hynes Convention Center.

Click here to schedule a private meeting with us: https://dls.com/event/car-tcr-2024/

We look forward to seeing you!

08/14/2024

Take advantage of our ongoing sale and receive 20% off AllCells® Cryopreserved Cord Blood CD34+ Cells. Isolated from a single umbilical cord, these high-quality, high-purity cells are ideal for applications where bypassing HLA mismatch is required.

Reserve your vials today using promo code 20OFFCB: https://allcells.com/research-grade-tissue-products/cord-blood/?

Our cord blood is collected from donors following IRB-approved protocols, and the HSPCs are isolated using a positive immunomagnetic bead separation process.

Learn more: https://allcells.com/research-grade-tissue-products/cord-blood/

08/09/2024

A recent clinical trial has shown promising results, with three autoimmune disease patients responding positively to an allogeneic CD19-directed CAR-T therapy.

Read more: https://www.fiercebiotech.com/biotech/allogeneic-car-t-cells-used-treat-autoimmune-disease-first-time

This is the first clinical proof-of-concept demonstrating the efficacy and safety of an “off the shelf” cell therapy for autoimmune disease, marking a significant milestone for the field!

Learn how Discovery's expertise in donor recruitment and management can propel advancements in allogeneic cell therapy development for cancers, autoimmune diseases, and more: https://allcells.com/services/donor-management-program/

Three people with autoimmune diseases have responded positively to allogeneic CAR-T therapy, marking a first for the "off-the-shelf" cell therapy tech. | In a first, three patients with autoimmune diseases have responded positively to allogeneic CAR-T therapy. The study, conducted in China and publi...

07/24/2024

Did you know we are the only CGT starting materials provider offering both volume-based and cell-count-based RUO Leukopaks? This dual capability offers CGT developers the ability to choose the best option for their specific project needs, timelines, and budgets—without compromising on quality.

AllCells® Volume-Based Leukopaks: The standard format for transitioning from RUO to GMP with an average of 15 billion total nucleated cells (TNCs), ideal for maximizing project flexibility.

AllCells® Cell-Count-Based Leukopaks: A more budget-friendly option of 10 billion TNCs with enhanced lot-to-lot consistency.

Contact us to learn more about these options: https://allcells.com/research-grade-tissue-products/leukopak/?

06/06/2024

AllCells® Matched Immune Cell Subsets are cryopreserved and assay-ready, empowering scientists to overcome cell source variability and achieve high-quality, reliable results in CGT, immunotherapy, infectious disease, and vaccine development.

Request a quote today and get 20% off with promo code “Match20”. No minimum purchase is required. Take advantage of this special deal today: https://allcells.com/isolated-cell-products/ -sets

05/02/2024

Discovery Life Sciences specializes in leukapheresis and custom prospective collections of high-quality CGT starting materials. Our AllCells RUO and GMP products, along with integrated analytical services, have supported complex CGT programs transition seamlessly from early discovery to process development and manufacturing, with an average 98% collection deliverability rate.

Connect with us today and let’s shape the future of CGT together!